Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study
A triple combination treatment — dendritic cell vaccination plus …
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreA triple combination treatment — dendritic cell vaccination plus …
Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from…
Multiple myeloma patients whose cancer progresses early after first-line…
Twice‐weekly Ninlaro (ixazomib) plus Revlimid…
Prescribing information for Kyprolis (carfilzomib) in the U.S. will…
Genetic analysis of multiple myeloma DNA from two different…